Literature DB >> 10430752

Enhanced proteoglycan deposition in the airway wall of atopic asthmatics.

J Huang1, R Olivenstein, R Taha, Q Hamid, M Ludwig.   

Abstract

Increased extracellular matrix (ECM) deposition in the airway wall contributes to the airway wall remodeling observed in asthmatics. Although alterations in collagen have been well described, less is known about changes in other components of the ECM, particularly proteoglycans (PGs). Endobronchial biopsies were obtained from seven patients with mild atopic asthma and six normal control subjects. Tissues were blocked in OCT and frozen in isopentane. Sections were immunostained with antibodies for the small leucine-rich PGs, lumican, biglycan, decorin, and fibromodulin and for versican, a large chondroitin sulfate PG. We calculated the area of positive staining in the subepithelial layer, correcting for basement membrane length. Lumican, biglycan, and versican were localized predominantly in the subepithelial layer of the airway wall in all groups. PG deposition was significantly increased in asthmatics as compared with that in control subjects. Furthermore, the degree of PG immunoreactivity was significantly correlated with airway responsiveness in the asthmatics (lumican; r = -0.77, p < 0.05; biglycan: r = -0.76, p < 0.05; versican: r = -0.74, p = 0.06). Our results suggest that PGs may play a role in airway wall remodeling and thereby, airway mechanics in asthma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430752     DOI: 10.1164/ajrccm.160.2.9809040

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  57 in total

Review 1.  Pharmacotherapy and airway remodelling in asthma?

Authors:  P A Beckett; P H Howarth
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

Review 2.  Airway remodelling in asthma: from benchside to clinical practice.

Authors:  Céline Bergeron; Meri K Tulic; Qutayba Hamid
Journal:  Can Respir J       Date:  2010 Jul-Aug       Impact factor: 2.409

Review 3.  Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection.

Authors:  Sean Gill; Thomas N Wight; Charles W Frevert
Journal:  Anat Rec (Hoboken)       Date:  2010-06       Impact factor: 2.064

Review 4.  Pathogenetic and prognostic roles of bloodborne fibrocytes in asthma.

Authors:  Sabrina Mattoli
Journal:  J Zhejiang Univ Sci B       Date:  2015-08       Impact factor: 3.066

5.  Lung lining fluid glutathione attenuates IL-13-induced asthma.

Authors:  Matthew H Lowry; Brian P McAllister; Jyh-Chang Jean; Lou Ann S Brown; Rebecca P Hughey; William W Cruikshank; Sal Amar; Edgar C Lucey; Kathleen Braun; Pamela Johnson; Thomas N Wight; Martin Joyce-Brady
Journal:  Am J Respir Cell Mol Biol       Date:  2007-12-06       Impact factor: 6.914

Review 6.  Motility, survival, and proliferation.

Authors:  William T Gerthoffer; Dedmer Schaafsma; Pawan Sharma; Saeid Ghavami; Andrew J Halayko
Journal:  Compr Physiol       Date:  2012-01       Impact factor: 9.090

Review 7.  Interplay of extracellular matrix and leukocytes in lung inflammation.

Authors:  Thomas N Wight; Charles W Frevert; Jason S Debley; Stephen R Reeves; William C Parks; Steven F Ziegler
Journal:  Cell Immunol       Date:  2016-12-23       Impact factor: 4.868

Review 8.  The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease.

Authors:  Sharon L I Wong; Maria B Sukkar
Journal:  Br J Pharmacol       Date:  2016-11-25       Impact factor: 8.739

9.  Sputum hyaluronan and versican in severe eosinophilic asthma.

Authors:  Andrew G Ayars; Leonard C Altman; Sue Potter-Perigo; Katherine Radford; Thomas N Wight; Parameswaran Nair
Journal:  Int Arch Allergy Immunol       Date:  2012-12-14       Impact factor: 2.749

10.  Tgf-Beta isoform specific regulation of airway inflammation and remodelling in a murine model of asthma.

Authors:  Stephen E Bottoms; Jane E Howell; Alistair K Reinhardt; Iona C Evans; Robin J McAnulty
Journal:  PLoS One       Date:  2010-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.